Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07559786 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Multicenter, Open-label, Randomized, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy

Study acronym: ARL-LS-SCLC
StatusRecruiting
PhasePhase 2
Started2026-07-17
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Apr 1, 2029 → Jul 17, 2029
See other at-risk trials from Henan Cancer Hospital

Amendment history

2026-07-17
Study Identification, Study Status, Study Description, Arms and Interventions, Eligibility, Contacts/Locations v1
Recruitment opened
Primary completion pushed: 2029-04-01 → 2029-07-17
Completion pushed: 2029-04-01 → 2029-07-17
Start date2026-04-01→2026-07-17
Study sites1→2
InterventionsInvolved-Field Radiotherapy (IFRT) group (Drug), Nodal residual-field radiotherapy group (Drug)→CCRT(Employed residual field irradiation(RFI)) (Other), CCRT(Involved-Field Radiotherapy (IFRT)) (Other)
Eligibility criteriarevised
[...] ccepted contraceptive method during study treatment and for 36 months after treatment completion. For females of reproduct [...]
Study title+4 characters
A Multicenter, RandomizedOpen-label, CohortRandomized, Prospective Clinical Study of Adebrelimab Consolidation Th [...]
2026-04-27
Original filing
This study aims to evaluate the efficacy and safety of adebrelimab consolidation therapy after progression-free response of concurrent chemoradiotherapy in patients with limited-stage small cell lung cancer. This study plans to enroll patients with untreated limited-stage small cell lung cancer who meet the inclusion criteria. The eligible patients will be randomly divided 1:1 into two groups to receive treatment regimens for residual lymph nodes and involved irradiated areas. That is, carboplatin AUC 5, D1 + etoposide 100 mg/m…\^2 on days 1, 2, and 3 + thoracic radiotherapy (residual lymph nodes or involved irradiated areas), with each 3-week cycle. After 4 cycles of concurrent chemoradiotherapy, the non-progressing subjects will continue to receive adebrelimab (1200 mg, IV, Q3W) maintenance therapy.
Trial Details
NCT Number NCT07559786
Lead Sponsor Henan Cancer Hospital
Conditions SCLC, Limited Stage
Enrollment 200 participants
Start Date 2026-07-17
Primary Completion 2029-07-17 (estimated)
Study Completion 2029-07-17 (estimated)
Updated on ClinicalTrials.gov 2026-07-21